This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11140%2F13%3A10134202%21RIV14-MSM-11140___/
n16http://localhost/temp/predkladatel/
n4http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/resource/domain/vavai/subjekt/
n10http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n13http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n5http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11140%2F13%3A10134202%21RIV14-MSM-11140___
rdf:type
skos:Concept n10:Vysledek
rdfs:seeAlso
http://download.journals.elsevierhealth.com/pdfs/journals/0010-8650/PIIS0010865012001373.pdf
dcterms:description
Aspirin reduces vasculardeath by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful. The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely. Aspirin reduces vasculardeath by approximately 15% and nonfatal vascular events by about 30% in secondary prevention. The evidence in primary prevention in non-diabetic subjects is not so powerful. The benefit of aspirin primary prevention in type 2 diabetes remains to be advocated definitely.
dcterms:title
Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients? Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?
skos:prefLabel
Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients? Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular diseases. Is there any difference between diabetic and non-diabetic patients?
skos:notation
RIV/00216208:11140/13:10134202!RIV14-MSM-11140___
n10:predkladatel
n11:orjk%3A11140
n3:aktivita
n9:I
n3:aktivity
I
n3:cisloPeriodika
2
n3:dodaniDat
n14:2014
n3:domaciTvurceVysledku
n4:5472539 n4:1903578
n3:druhVysledku
n5:J
n3:duvernostUdaju
n18:S
n3:entitaPredkladatele
n20:predkladatel
n3:idSjednocenehoVysledku
67533
n3:idVysledku
RIV/00216208:11140/13:10134202
n3:jazykVysledku
n13:eng
n3:klicovaSlova
type2diabetes; primary prevention; cardiovasculardisease; Aspirin
n3:klicoveSlovo
n12:primary%20prevention n12:Aspirin n12:cardiovasculardisease n12:type2diabetes
n3:kodStatuVydavatele
CZ - Česká republika
n3:kontrolniKodProRIV
[1BD66C3AB2AD]
n3:nazevZdroje
Cor et Vasa
n3:obor
n15:FA
n3:pocetDomacichTvurcuVysledku
2
n3:pocetTvurcuVysledku
2
n3:rokUplatneniVysledku
n14:2013
n3:svazekPeriodika
55
n3:tvurceVysledku
Rosolová, Hana Nussbaumerová, Barbora
s:issn
0010-8650
s:numberOfPages
6
n17:doi
10.1016/j.crvasa.2012.11.019
n16:organizacniJednotka
11140